MDGL

Madrigal Pharmaceuticals
MDGL

Latest price

Financial Snapshot

gainify

Market Data

Market Cap
$6.82B
EV
$6.01B
Shares Outstanding
23.15M
Beta
-0.69

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$414.07
P/E 2025E
-
P/Revenue 2025E
11.56x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Madrigal Pharmaceuticals, Inc.

gainify
MDGL

Madrigal Pharmaceuticals, Inc.

MDGL

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid ho...

Sector

Healthcare

Industry

Biotechnology

CEO

Sibold, William

Employees

528

IPO Date

2007-02-06

Headquarters

Four Tower Bridge, Suite 200, 200 Barr Harbor Drive, West Conshohocken, Pennsylvania, 19428, United States

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved